*Benign v malignant epithelium in tamoxifen users: p<0.05; †tamoxifen v no tamoxifen: p<0.05; ‡benign v malignant stroma in tamoxifen users: p<0.05; §benign v malignant stroma in non-users: p<0.05. | ||||
ER positive | PR positive | |||
Epithelium n (%) | Stroma n (%) | Epithelium n (%) | Stroma n (%) | |
Benign endometrium | ||||
(I) Tamoxifen | 34 (97)* | 33 (94)* | 34 (97) | 27 (84)†‡ |
(II) No tamoxifen | 22 (92) | 18 (75)§ | 21 (88) | 13 (54)§ |
Endometrial cancer | ||||
(III) Tamoxifen | 9 (60)† | 4 (27) | 11 (73) | 5 (33) |
(IV) No tamoxifen | 44 (88) | 16 (32) | 40 (80) | 5 (10) |